Clarifying the Optimal Application of SLT Therapy Trial
Part of paid clinical trials in Laguna Hills, California.
- Sponsor
- University of Pittsburgh
- Study ID
- NCT04967989
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Glaucoma and Ocular Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Low Energy SLT — PROCEDURESLT performed at low energy
- Standard Energy SLT — PROCEDURESLT performed at standard energy
Study Details
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Key Dates
- Start date
- Sep 7, 2021
- Status verified
- Sep 2025
- Primary completion
- Jun 30, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 790 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Trial 1: Initial standard energy SLTStandard energy SLT is performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.
- Experimental: Trial 2: Month 12 Randomization: Annual Low Energy Repeat SLTAt month 12, eligible subjects will be randomized to undergo repeat SLT either annually at low energy or as needed at standard energy. Low energy SLT will consist of 100 treatment spots delivered at 0.4 mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3 mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ is no bubbles are seen with 5 consecutive spots.
- Active Comparator: Trial 2: Month 12 Randomization: As-Needed Repeat SLT at Standard EnergyAt month 12, eligible subjects will be randomized to undergo repeat SLT either annually at low energy or as needed at standard energy. Standard SLT will be performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.
- Experimental: Trial 1: Initial Low Energy SLTNote: This arm was discontinued following a planned interim analysis. Low energy SLT will consist of 100 treatment spots delivered at 0.4 mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3 mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ if no bubbles are seen with 5 consecutive spots.
Primary Outcome Measure
12-month survival [ Time Frame: 12 months ]
Central Contacts
- Tony Realini, MD, MPH3045986926
Locations (28)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Harvard Eye Associates | Laguna Hills | California | 92653 | Ye Elaine Wang, MD (PRINCIPAL_INVESTIGATOR) |
| Doheny Eye Center UCLA | Pasadena | California | 91105 | Judy L Chen, MD (PRINCIPAL_INVESTIGATOR) |
| University of California, Davis | Sacramento | California | 95817 | James Brandt, MD (PRINCIPAL_INVESTIGATOR) |
| University of California, San Francisco | San Francisco | California | 94158 | Ying Han, MD (PRINCIPAL_INVESTIGATOR) |
| Mile High Eye Institute | Sheridan | Colorado | 80110 | Zachary Vest, MD (PRINCIPAL_INVESTIGATOR) |
| Clear Vue Laser Eye Center | Lakeworth | Florida | 33467 | Monique Barbour, MD (PRINCIPAL_INVESTIGATOR) |
| Northwestern Medical Group | Chicago | Illinois | 60615 | Angelo Tanna, MD (PRINCIPAL_INVESTIGATOR) |
| Chicago Arbor Eye Institute | Orland Park | Illinois | 60467 | Richard Quinones, MD (PRINCIPAL_INVESTIGATOR) |
| Illinois Eye Center | Peoria | Illinois | 61615 | Sachin Kalarn, MD (PRINCIPAL_INVESTIGATOR) |
| Wilmer Eye Institute Johns Hopkins | Baltimore | Maryland | 21287 | Pradeep Ramulu, MD (PRINCIPAL_INVESTIGATOR) |
| Massachusetts Eye and Ear | Boston | Massachusetts | 02114 | Michael Cheung Michael Lin, MD (PRINCIPAL_INVESTIGATOR) |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02451 | Tejinder Kaur Theodor Sauer, MD (PRINCIPAL_INVESTIGATOR) |
| Mark Latina, LLC | Reading | Massachusetts | 01867 | Mark Latina, MD (PRINCIPAL_INVESTIGATOR) |
| University of Michigan Kellogg Eye Center | Ann Arbor | Michigan | 48105 | Amanda Bicket, MD (PRINCIPAL_INVESTIGATOR) |
| Kresge Eye Institute Wayne State University | Detroit | Michigan | 48201 | Bret Hughes, MD (PRINCIPAL_INVESTIGATOR) |
| New York Eye Surgery Associates | The Bronx | New York | 10469 | Nathan Radcliffe, MD (PRINCIPAL_INVESTIGATOR) |
| Cleveland Clinic Cole Eye Institute | Cleveland | Ohio | 44195 | Ang Li, MD (PRINCIPAL_INVESTIGATOR) |
| University Hospitals Eye Institute | Cleveland | Ohio | 44106 | Douglas Rhee, MD (PRINCIPAL_INVESTIGATOR) |
| Devers Eye Institute | Portland | Oregon | 97210 | Robert Kinast, MD (PRINCIPAL_INVESTIGATOR) |
| Eye Care Specialists | Kingston | Pennsylvania | 18704 | Daniel Lutz, MD (PRINCIPAL_INVESTIGATOR) |
| Scheie Eye Institute | Philadelphia | Pennsylvania | 19104 | Ahmara Ross, MD (PRINCIPAL_INVESTIGATOR) |
| Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | Lauren Hock, MD (PRINCIPAL_INVESTIGATOR) |
| UPMC Eye Center | Pittsburgh | Pennsylvania | 15213 | - |
| Vanderbilt Eye Institute | Nashville | Tennessee | 37232 | Rachel Kuchtey, MD (PRINCIPAL_INVESTIGATOR) |
| Ophthalmology Associates | Fort Worth | Texas | 76102 | Brian Flowers, MD (PRINCIPAL_INVESTIGATOR) |
| Spokane Eye Clinical Research | Spokane | Washington | 99204 | Rory Allar, MD (PRINCIPAL_INVESTIGATOR) |
| West Virginia University | Morgantown | West Virginia | 26505 | Tony Realini, MD, MPH (PRINCIPAL_INVESTIGATOR) |
| University of Wisconsin-Madison | Madison | Wisconsin | 53705 | Yao Liu, MD (PRINCIPAL_INVESTIGATOR) |